THE EMERGENCE & EPIDEMIC CHARACTERISTICS OF THE SARS‐COV‐ 2 OMICRON VARIANT
Krishna Ghule*, Mohammed Rayees Ahmad, Aditya Gunale and Mahesh Gore
Abstract
Recently, the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) Omicron variant (B.1.1.529) was first identified in
Botswana in November 2021. It was first reported to the World Health
Organization (WHO) on November 24. On November 26, 2021,
according to the advice of scientists who are part of the WHO's
Technical Advisory Group on SARS‐CoV‐2 Virus Evolution
(TAG‐VE), the WHO defined the strain as a variant of concern (VOC)
and named it Omicron. Compared to the other four VOCs (Alpha,
Beta, Gamma, and Delta), the Omicron variant was the most highly
mutated strain, with 50 mutations accumulated throughout the genome.
The Omicron variant contains at least 32 mutations in the spike protein, which was twice as
many as the Delta variant. Studies have shown that carrying many mutations can increase
infectivity and immune escape of the Omicron variant compared with the early wild‐type
strain and the other four VOCs. The Omicron variant is becoming the dominant strain in
many countries worldwide and brings new challenges to preventing and controlling
coronavirus disease 2019 (COVID‐19). The current review article aims to analyze and
summarize information data about the biological characteristics of amino acid mutations, the
epidemic characteristics, immune escape, and vaccine reactivity of the Omicron variant,
hoping to provide a scientific reference for monitoring, prevention, and vaccine development
strategies for the Omicron variant.
Keywords: Omicron, Sars-Cov-V2, Vaccine, Anti-Body, Varients.
[Full Text Article]